This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
by Zacks Equity Research
Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.
Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day.
Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound
by Zacks Equity Research
LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
by Zacks Equity Research
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
by Zacks Equity Research
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
by Zacks Equity Research
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
by Zacks Equity Research
MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
Zacks.com featured highlights include Norwegian Cruise Line, Eli Lilly, The Progressive and Fortinet
by Zacks Equity Research
Norwegian Cruise Line, Eli Lilly, The Progressive and Fortinet have been highlighted in this Screen of The Week article.
The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace
by Zacks Equity Research
Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.
Top Research Reports for Eli Lilly, Chevron & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Chevron Corporation (CVX) and Abbott Laboratories (ABT), as well as a micro-cap stocks Bridger Aerospace Group Holdings, Inc. (BAER).
Buy 4 Top-Ranked Stocks to Play Likely Earnings Beat
by Sanghamitra Saha
Top-ranked stocks Norwegian Cruise Line (NCLH), Eli Lilly (LLY), The Progressive (PGR) and Fortinet (FTNT) are likely to beat on earnings in their upcoming releases.
Here's Why You Should Consider Buying Akebia (AKBA) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
by Zacks Equity Research
The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
by Kinjel Shah
Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.
Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
by Kinjel Shah
LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug
by Zacks Equity Research
Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
by Zacks Equity Research
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Company News for Aug 21, 2024
by Zacks Equity Research
Companies In The News Are: LLY, BA, AS, MDT.
Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly
by Zacks Equity Research
Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
by Andrew Rocco
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
by Kinjel Shah
After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.